Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 11/20 | 0.37 |
| ▸ | MMP2 | P08253 | 10/20 | 0.37 |
| ▸ | MMP9 | P14780 | 8/20 | 0.37 |
| ▸ | MMP3 | P08254 | 6/20 | 0.36 |
| ▸ | MMP8 | P22894 | 5/20 | 0.36 |
| ▸ | MMP14 | P50281 | 5/20 | 0.36 |
| ▸ | MMP1 | P03956 | 5/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MMP7 | P09237 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.32 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5717412 | 0.90 | MMP2 (0.39) | MMP13MMP2MMP9MMP3MMP8 | |
| SCHEMBL5717231 | 0.86 | MMP13 (0.49) | MMP13MMP2MMP9MMP3MMP8 | |
| SCHEMBL6097518 | 0.84 | MMP13 (0.43) | MMP13MMP2MMP9MMP3MMP8 | |
| SCHEMBL5840614 | 0.84 | MMP9 (0.39) | MMP13MMP2MMP9MMP3MMP8 | |
| SCHEMBL5908513 | 0.82 | MMP8 (0.50) | MMP13MMP2MMP9MMP3MMP8 | |
| SCHEMBL6094620 | 0.80 | MMP13 (0.43) | MMP13MMP2MMP9MMP3MMP8 | |
| SCHEMBL8291931 | 0.79 | MMP13 (0.40) | MMP13MMP2MMP9MMP3MMP8 | |
| SCHEMBL6230179 | 0.78 | MMP8 (0.39) | MMP13MMP2MMP9MMP3MMP8 | |
| SCHEMBL8291093 | 0.78 | HPGD (0.33) | — | |
| SCHEMBL8291695 | 0.77 | MMP2 (0.41) | MMP13MMP2MMP9MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119203-B2 | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| US-20050209278-A1 | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2005-09-22 | — | — | US | disclosed |
| WO-2005042521-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | WO | disclosed |
| EP-1501827-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACID AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20050009838-A1 | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| WO-2003091247-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209278-A1 | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | MMP1, PREP, MMP3 | MMP13 6/4885MMP2 4/4885MMP9 5/4885 |
| US-20050009838-A1 | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | MMP1, PREP, MMP3 | MMP13 6/4885MMP2 4/4885MMP9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.